Brokerage firm Baird Downgrades its rating on Laboratory Corp. of America Holdings(LH). The shares have been rated Neutral. Previously, the analysts had a Outperform rating on the shares. The rating by Baird was issued on Feb 6, 2017.
In a different note, Deutsche Bank said it Initiates Coverage On Laboratory Corp. of America Holdings, according to a research note issued on Jan 18, 2017. In the research note, the firm Announces the price-target to $170 per share. The shares have been rated ‘Buy’ by the firm.
Laboratory Corp. of America Holdings (LH) made into the market gainers list on Tuesdays trading session with the shares advancing 0.57% or 0.74 points. Due to strong positive momentum, the stock ended at $130.6, which is also near the day’s high of $130.69. The stock began the session at $129.63 and the volume stood at 9,33,986 shares. The 52-week high of the shares is $141.32 and the 52 week low is $97.79. The company has a current market capitalization of $13,452 M and it has 10,30,00,000 shares in outstanding.
Laboratory Corp. of America Holdings(LH) last announced its earnings results on Oct 26, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $2.37B. Analysts had an estimated revenue of $2.37B. Earnings per share were $2.25. The reported EPS was above estimates by $0.04 or NaN%. Analysts had estimated an EPS of $2.29.
Several Insider Transactions has been reported to the SEC. On Aug 11, 2016, Lisa J Uthgenannt (Chief Human Resources Officer) sold 1,177 shares at $140.00 per share price.Also, On Aug 8, 2016, Glenn A Eisenberg (Chief Financial Officer, EVP) sold 8,000 shares at $140.38 per share price.On Aug 8, 2016, Robert E Jr Mittelstaedt (director) sold 992 shares at $140.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.